Real World Study of Linperlisib for Lymphoma Treatment
This is a multicenter, non-interventional and observational real-world study to evaluate the efficacy and safety of linperlisib in patients with lymphoma.
Focus on the Lymphoma Including B/T-cell Lymphoma
DRUG: Linperlisib
Rate of adverse events (AEs)/ serious adverse events (SAEs), Rate of adverse events (AEs)/ serious adverse events (SAEs) in patients with lymphoma receiving linperlisib therapy, up to 4 weeks after the last dose
Complete response rate, Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria., 6 months|Progression-free survival, Progression-free survival was defined as the time from the date of enrollment until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first., 1 years and 2 years|Overall survival, Overall survival was defined as the time from the date of enrollment to the date of death from any cause., Baseline up to data cut-off (up to approximately 2 years)|Duration of response, Duration of response was defined as the time from the date of favorable response until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, Baseline up to data cut-off (up to approximately 2 years)
This is a multicenter, non-interventional and observational real-world study to evaluate the efficacy and safety of linperlisib in patients with lymphoma.